Organ-sparing therapy should be offered more widely for bladder cancer, doctors say
Their advice is based on favourable overall survival rates in those undergoing trimodality therapy versus radical cystectomy.
Organ-sparing trimodality therapy should be offered to all suitable patients with muscle-invasive bladder cancer, not just those who are ineligible for surgery, according to urologic oncologists.
Their recommendation is based on favourable odds of overall survival, and similar cancer-specific and disease-free survival, in patients undergoing trimodality therapy versus radical cystectomy.
